Abstract
BackgroundCognitive impairment may be seen in as many as 43–70% of patients with multiple sclerosis (MS) and may be observed in all MS subtypes. The Brief International Cognitive Assessment in Multiple Sclerosis (BICAMS) battery may be used to evaluate cognition status. The purpose of the current study is to validate the BICAMS battery in Turkish.MethodsPatients with MS attending our clinic between September 2014 and April 2015 were invited to participate. Healthy control participants were matched in terms of age, gender and years of education.ResultsOne hundred seventy-three MS patients and 153 healthy control participants were enrolled in the study. MS patients performed significantly worse in all trials than the members of the healthy control group. In addition, cognitive dysfunction was identified in 78 of the 173 (45.1%) patients. In the MS with cognitive impairment group, 64 out of 151 (42.4%) subjects were RRMS patients, 12 out of 18 (66.7%) were secondary progressive MS patients, and 2 out of 4 (50%) were primer progressive MS patients.ConclusionsThe BICAMS has been proposed for assessing cognitive impairment in MS patients. This study shows that the battery is suitable for use in Turkey.
Highlights
Cognitive impairment may be seen in as many as 43–70% of patients with multiple sclerosis (MS) and may be observed in all MS subtypes
One hundred seventy-three MS patients and 153 healthy controls were recruited to the study
The MS patients performed significantly worse in all trials than the members of the healthy group
Summary
Cognitive impairment may be seen in as many as 43–70% of patients with multiple sclerosis (MS) and may be observed in all MS subtypes. Cognitive impairment is common in multiple sclerosis (MS), and approximately half of patients with MS present with cognitive impairment that adversely impacts on aspects of both patients’ and caregivers’ everyday lives [1, 2]. It is demonstrable in all disease stages and subtypes, in up to 40% of newly diagnosed individuals with clinically isolated syndrome and relapsing remitting MS (RRMS) [3] and in up to 60% of those with secondary progressive MS (SPMS) [4]. The secondary objective was to measure the impact of cognitive impairment on patients’ quality of life and the effect of fatigue on patients’ cognitive state by assessing correlations between BICAMS performance and the Modified Fatigue Impact Scale (MFIS) and the Multiple Sclerosis International Quality of Life (MUSIQoL) questionnaire
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
